Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminosin
- Development stage
- Unknown
- Lead developer
- Ibn Sina Pharmaceutical Industry
- Modality
- Small Molecules
- Administration
- Intravenous, Parenteral
01
Overview
Aminosin is an approved intravenous infusion product developed and marketed by Ibn Sina Pharmaceutical Industry in Bangladesh. It is a sterile aqueous parenteral nutrition solution containing a combination of essential and non-essential amino acids, D-sorbitol, and electrolytes. Aminosin serves as a systemic nitrogen source to promote protein synthesis, maintain nitrogen balance, and support tissue repair. It is indicated for patients requiring intravenous nutritional support, including those with basal amino acid requirements, and is used to facilitate recovery in patients undergoing surgery or suffering from burns, renal insufficiency, hepatic insufficiency, and cancer.
- Brand names
- Aminosin
- Other names
- amino acids + D-sorbitol + electrolytesaminosine
Beyond the preview
Go deeper on Aminosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aminosin.